Boston Scientific Jumps On Upbeat Q2, FY22 Guidance
Boston Scientific Corp (NYSE:BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%. The Company achieved…
Benzinga ·
Benzinga
